Close Menu
InfoQuest Network
  • News
  • World
    • United States
    • Canada
    • Europe
    • Asia
    • Latin America
    • Australia
    • Africa
  • Politics
  • Business
    • Personal Finance
    • Finance
    • Markets
    • Startup
    • Investing
    • Innovation
    • Billionaires
    • Crypto
  • Tech
  • Lifestyle
  • Sports
  • Travel
  • More
    • Science
    • Entertainment
    • Health & Wellness
    • Immigration
Trending

Smith Hits Hard with Injured Finger

July 5, 2025

Montreal Comiccon Might Benefit from U.S. Trade War, Says Spokesperson

July 5, 2025

Texas Flood Underscores ‘Neglected’ Weather Alert System Trump Plans to Modernize

July 5, 2025
Facebook X (Twitter) Instagram
Smiley face Weather     Live Markets
  • Newsletter
  • Advertise
Facebook X (Twitter) Instagram YouTube
InfoQuest Network
  • News
  • World
    • United States
    • Canada
    • Europe
    • Asia
    • Latin America
    • Australia
    • Africa
  • Politics
  • Business
    • Personal Finance
    • Finance
    • Markets
    • Startup
    • Investing
    • Innovation
    • Billionaires
    • Crypto
  • Tech
  • Lifestyle
  • Sports
  • Travel
  • More
    • Science
    • Entertainment
    • Health & Wellness
    • Immigration
InfoQuest Network
  • News
  • World
  • Politics
  • Business
  • Finance
  • Entertainment
  • Health & Wellness
  • Lifestyle
  • Technology
  • Travel
  • Sports
  • Personal Finance
  • Billionaires
  • Crypto
  • Innovation
  • Investing
  • Markets
  • Startup
  • Immigration
  • Science
Home»Business»Markets»Is Merck Stock poised for an earnings beat?
Markets

Is Merck Stock poised for an earnings beat?

News RoomBy News RoomJuly 27, 20240 ViewsNo Comments2 Mins Read
Share
Facebook Twitter LinkedIn Pinterest Email Reddit Telegram WhatsApp

Merck is set to report its Q2 2024 results, with expectations of revenue reaching $15.9 billion and adjusted earnings of $2.20. Keytruda is anticipated to be the primary driver of growth for the company, with sales estimated to exceed $7 billion, reflecting mid-teens year-over-year growth. Sales for Merck’s HPV vaccine, Gardasil, are also expected to rise in the mid-teens. While the company may have a positive Q2, analysts believe that there is limited room for stock growth. Merck’s stock performance has been somewhat inconsistent in recent years, underperforming the S&P 500 in 2021 and 2023.

Despite the challenges faced by individual stocks in beating the S&P 500, the Trefis High Quality Portfolio has consistently outperformed the benchmark index over the past few years. As the macroeconomic environment remains uncertain, with high oil prices and elevated interest rates, the question arises whether Merck will underperform the S&P in the next 12 months or experience a strong jump. From a valuation perspective, Merck seems to be appropriately priced, with an estimated valuation of $135 per share, close to the current market price of $127. The company is trading at 5x revenues compared to the 4.5x average over the last five years.

In the previous quarter, Merck saw a 9% year-over-year increase in revenue, driven by market share gains for Keytruda and sales growth for Gardasil. Adjusted gross margin also expanded, resulting in a 48% year-over-year increase in the bottom line. Keytruda and Gardasil remain the key growth drivers for the latest quarter, with Keytruda expanding into new indications and Gardasil experiencing strong demand in China. However, generic competition for Merck’s diabetes drugs may pose a challenge. The company’s management has indicated a likely expansion in the operating margin for 2024.

Kangen Water

While Merck’s stock appears reasonably priced, it is essential to examine how the company’s peers are performing on key metrics. Comparisons to other companies across industries can provide valuable insights. Overall, analysts have mixed views on Merck’s performance in the upcoming quarter, with some concerns about the stock’s growth potential. Investors will be closely watching the company’s Q2 results to gain a better understanding of its revenue and earnings performance.

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram WhatsApp

Related News

Three Dividend Stocks Offering More than 7% Returns in Any Market

August 9, 2024

Reflections on 2008: Navigating a Challenging Economy with Ford

August 9, 2024

Can Baidu’s AI Innovations Drive Stock Growth After Q2 Results?

August 8, 2024

Anticipating the Outcome of Wheaton Precious Metals’ Q2 Results

August 8, 2024

What Factors are Contributing to the Decline in Nintendo Stock Prices?

August 8, 2024

Markets Aiming for Back-to-Back Winning Days

August 8, 2024
Add A Comment
Leave A Reply Cancel Reply

Top News

Montreal Comiccon Might Benefit from U.S. Trade War, Says Spokesperson

July 5, 2025

Texas Flood Underscores ‘Neglected’ Weather Alert System Trump Plans to Modernize

July 5, 2025

Saints Star Alvin Kamara Requests a Re-Do After Disastrous First Pitch at Cubs-Cardinals Game

July 5, 2025

Subscribe to Updates

Get the latest news and updates directly to your inbox.

Advertisement
Kangen Water
InfoQuest Network
Facebook X (Twitter) Instagram YouTube
  • Home
  • Privacy Policy
  • Terms of use
  • Press Release
  • Advertise
  • Contact
© 2025 Info Quest Network. All Rights Reserved.

Type above and press Enter to search. Press Esc to cancel.